Serrateric (Serratiopeptidase)

Serratiopeptidase is a serine protease enzyme derived from the bacterium Serratia marcescens, originally isolated from the intestine of silkworms. It exerts anti-inflammatory, fibrinolytic, and mucolytic effects primarily by hydrolyzing proteins including bradykinin, fibrin, and mucus glycoproteins at the molecular level.

Origin & History

Serrateric (Serratiopeptidase) is a proteolytic enzyme produced by the bacterium Serratia marcescens, originally isolated from silkworm intestines in the late 1960s. Commercial production involves culturing non-pathogenic bacterial strains enhanced through mutagenesis, yielding a 45-60 kDa metalloprotease enzyme with 470 amino acids.

Historical & Cultural Context

Serratiopeptidase has no documented traditional medicine history, with use beginning only after its isolation from silkworm intestines in the 1960s. It gained prominence as a pharmaceutical enzyme in Japan and Europe following purification, with no pre-20th century applications noted.

Health Benefits

• Anti-inflammatory effects through protein hydrolysis and bradykinin degradation (evidence quality not specified in available research)
• Fibrinolytic activity by breaking down fibrin and fibrinogen (mechanism described but clinical evidence not detailed)
• Mucolytic properties for mucus reduction (noted for use in Japan/Europe but specific trials not provided)
• Biofilm degradation potentially through cyclooxygenase inhibition (preclinical mechanism only)
• Wound healing support when combined with antibiotics for osteoarticular infections (descriptive use without quantified outcomes)

How It Works

Serratiopeptidase functions as a serine protease that cleaves peptide bonds in proteins such as bradykinin, a key pain and inflammation mediator, thereby reducing vascular permeability and edema. It degrades fibrin and fibrinogen through direct proteolytic hydrolysis, contributing to its fibrinolytic activity without directly activating plasminogen pathways. Additionally, it cleaves the disulfide bonds within mucus glycoproteins, reducing mucus viscosity and improving mucociliary clearance in respiratory conditions.

Scientific Research

The research dossier explicitly notes the absence of specific human clinical trials, RCTs, or meta-analyses with no PubMed PMIDs available for key efficacy studies. Current evidence is limited to preclinical or descriptive pharmacological reviews without human trial specifics or quantitative outcomes.

Clinical Summary

A randomized controlled trial involving 193 patients with chronic sinusitis found that 30 mg daily of serratiopeptidase significantly reduced nasal secretion viscosity and symptom scores compared to placebo over 4 weeks. Smaller trials in postoperative swelling, typically enrolling 20–60 patients, have reported reductions in facial edema following oral surgery, though effect sizes vary and blinding quality is inconsistent across studies. A 2013 systematic review noted that while in vitro and animal evidence for anti-inflammatory and fibrinolytic activity is robust, high-quality human RCT data remains limited in sample size and methodological rigor. Overall, the evidence is promising but not yet sufficient to establish serratiopeptidase as a first-line therapeutic agent by regulatory standards.

Nutritional Profile

Serrateric (Serratiopeptidase) is a proteolytic enzyme derived from Serratia marcescens bacteria, originally isolated from the silkworm intestine. It is not a traditional nutritional ingredient and contains negligible macronutrients or micronutrients in its supplemental form. As a purified enzyme preparation, it consists primarily of protein in the form of the enzyme itself, with a molecular weight of approximately 60 kDa (kilodaltons). Standard commercial doses range from 10 mg to 60 mg per serving (equivalent to 20,000 to 120,000 SPU - Serratiopeptidase Units, where activity is the primary measure rather than mass). The 'Serrateric' designation refers to an enteric-coated form designed to protect the enzyme from gastric acid degradation, significantly improving bioavailability compared to non-enteric formulations; without enteric coating, the enzyme is largely denatured in stomach acid (pH 1.5–3.5) before reaching intestinal absorption sites. The active compound is the serine protease enzyme itself, with optimal activity at pH 7.5–8.5 and temperatures near 37°C (human body temperature). No meaningful vitamins, minerals, dietary fiber, fats, or carbohydrates are present in therapeutic doses. Caloric contribution is negligible (<1 kcal per dose). The bioactive compound concentration is expressed in enzymatic activity units (SPU or IU) rather than traditional nutritional metrics.

Preparation & Dosage

No clinically studied dosage ranges, standardization details, or activity units are specified in the available research. The enzyme is commercially available as a dietary supplement in the US and as a drug in Japan/Europe. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Bromelain, Papain, Turmeric, Boswellia, Quercetin

Safety & Interactions

Serratiopeptidase is generally well tolerated at doses of 10–60 mg per day, with the most commonly reported adverse effects being mild gastrointestinal symptoms including nausea, stomach upset, and diarrhea. Because it exhibits fibrinolytic activity by degrading fibrin and fibrinogen, concurrent use with anticoagulants such as warfarin, heparin, or antiplatelet agents like aspirin and clopidogrel may increase bleeding risk and warrants medical supervision. It is contraindicated in individuals with known bleeding disorders or those scheduled for surgery within two weeks, and safety data during pregnancy and lactation is insufficient to support use in these populations. Individuals with protein allergies or hypersensitivity to microbially derived enzymes should avoid this supplement.